Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри
Статус
Фаза
Цел
Пол
Възраст
Държава
AI · cancer
Намерени 1,748 изпитвания за "cancer" Стр. 81 от 88
Active (not recruiting)
Multimodal Machine Learning Characterization of Solid Tumors
Adenocarcinoma of Prostate Radical Prostatectomy Hepatocellular Carcinoma (HCC) Glioma +2

This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)

Начало: 23.10.2022 Край: 31.12.2026 Възраст: от 18 г.
United States Ciprian Catana, MD, PhD NCT04687969
Active (not recruiting) Phase 1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 20.10.2022 Край: 01.09.2033 Възраст: от 18 г. Treatment
Australia, Germany, Italy +4 AbbVie NCT05259839
Active (not recruiting) Phase 2
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Sarcoma, Ewing Neoplasm Metastasis

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Начало: 20.09.2022 Край: 01.12.2026 Възраст: 1–39 г. Treatment
Australia, France, Germany +4 Eli Lilly and Company NCT05440786
Active (not recruiting) Phase 3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Начало: 15.09.2022 Край: 31.12.2027 Възраст: 18–130 г. Treatment
Argentina, Australia, Belgium +20 AstraZeneca NCT05450692
Active (not recruiting) Phase 1
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Extensive Stage Small Cell Lung Cancer

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Начало: 24.08.2022 Край: 28.08.2028 Възраст: от 18 г. Treatment
Australia, Belgium, Canada +11 Amgen NCT05361395
Active (not recruiting) Phase 2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Locally Advanced or Metastatic Urothelial Carcinoma

The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.

Начало: 17.08.2022 Край: 25.06.2026 Възраст: от 18 г. Treatment
Australia, Belgium, Canada +9 EMD Serono Research & Development Institute, Inc. NCT05327530
Active (not recruiting) Phase 3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

Начало: 05.08.2022 Край: 30.06.2027 Възраст: от 18 г. Treatment
Argentina, Australia, Brazil +16 Janssen Research & Development, LLC NCT05388669
Active (not recruiting) Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Carcinoma Non-Small-Cell Lung

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Начало: 03.08.2022 Край: 23.11.2026 Възраст: 18–130 г. Treatment
Argentina, Australia, Belgium +25 AstraZeneca NCT05261399
Active (not recruiting) Phase 1
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) after previous treatment with venetoclax. Chemotherapy drugs, such as navitoclax, venetoclax, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Начало: 29.07.2022 Край: 02.03.2027 Възраст: от 16 г.
United States City of Hope Medical Center NCT05222984
Active (not recruiting) Phase 3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Nonsquamous Non-small Cell Lung Cancer EGFR L858R EGFR Exon 19 Deletion

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

Начало: 08.07.2022 Край: 30.06.2026 Възраст: от 18 г. Treatment
Australia, Belgium, Canada +16 Daiichi Sankyo NCT05338970
Active (not recruiting) Phase 3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Ovarian Neoplasm Fallopian Tube Neoplasms Peritoneal Neoplasms

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Начало: 29.06.2022 Край: 01.03.2026 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +11 Corcept Therapeutics NCT05257408
Active (not recruiting) Phase 2
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Pancreatic Cancer

To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Начало: 20.05.2022 Край: 01.06.2026 Възраст: от 18 г. Treatment
Australia Australasian Gastro-Intestinal Trials Group NCT06094140
Active (not recruiting) Phase 3
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Colorectal Cancer (CRC)

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

Начало: 19.04.2022 Край: 14.05.2026 Възраст: 18–100 г. Treatment
Australia, France, Germany +9 Amgen NCT05198934
Active (not recruiting) Phase 3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Gastric Cancer Gastroesophageal Junction Adenocarcinoma

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.

Начало: 14.03.2022 Край: 29.01.2027 Възраст: 18–100 г. Treatment
Argentina, Australia, Belgium +24 Amgen NCT05111626
Active (not recruiting) Phase 3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Non-Small Cell Lung Cancer

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Начало: 21.02.2022 Край: 01.11.2032 Възраст: от 18 г.
Argentina, Brazil, Canada +17 AstraZeneca NCT05120349
Active (not recruiting) Phase 3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Начало: 07.02.2022 Край: 02.07.2030 Възраст: от 18 г. Treatment
Australia, Brazil, Canada +16 AstraZeneca NCT05221840
Active (not recruiting)
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
NASH - Nonalcoholic Steatohepatitis

The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).

Начало: 27.01.2022 Край: 30.08.2026 Възраст: 18–99 г.
United States Natalie Torok NCT05165446
Active (not recruiting) Phase 2/3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Начало: 15.01.2022 Край: 01.06.2026 Възраст: от 18 г. Treatment
Australia, Belgium, Czechia +9 ALX Oncology Inc. NCT05002127
Active (not recruiting) Phase 3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Ovarian Cancer Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants.

Начало: 13.12.2021 Край: 16.07.2027 Възраст: от 18 г. Treatment
Australia, Belgium, Brazil +21 Merck Sharp & Dohme LLC NCT05116189
Active (not recruiting) Phase 2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Melanoma Merkel Cell Carcinoma, Unspecified Renal Cell Carcinoma Non Small Cell Lung Cancer

The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.

Начало: 09.12.2021 Край: 01.07.2025 Възраст: от 18 г. Diagnostic
Australia, Belgium, Netherlands +3 ImaginAb, Inc. NCT05013099
1 … 79 80 81 82 83 … 88